CNCE - Concert Pharmaceuticals Stock Price, News & Analysis

$22.22 0.06 (0.27 %)
(As of 11/23/2017 03:21 PM ET)
Previous Close$22.16
Today's Range$21.78 - $22.59
52-Week Range$7.11 - $22.59
Volume194,500 shs
Average Volume239,669 shs
Market Capitalization$504.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49

About Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.


Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNCE
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio28.18%
Quick Ratio28.18%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$170,000.00
Price / Sales2,976.17
Cash FlowN/A
Price / CashN/A
Book Value$8.60 per share
Price / Book2.58

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$3.72
Net Income$-50,720,000.00
Net Margins62.31%
Return on Equity-51.48%
Return on Assets-42.46%

Miscellaneous

Employees69
Outstanding Shares22,770,000

Frequently Asked Questions for Concert Pharmaceuticals (NASDAQ:CNCE)

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) issued its earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.03. The biotechnology company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.06 million. Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. View Concert Pharmaceuticals' Earnings History.

Where is Concert Pharmaceuticals' stock going? Where will Concert Pharmaceuticals' stock price be in 2017?

4 brokers have issued 1 year target prices for Concert Pharmaceuticals' stock. Their forecasts range from $21.00 to $30.00. On average, they expect Concert Pharmaceuticals' stock price to reach $24.75 in the next twelve months. View Analyst Ratings for Concert Pharmaceuticals.

What are Wall Street analysts saying about Concert Pharmaceuticals stock?

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (11/15/2017)
  • 2. HC Wainwright analysts commented, "de-risked platform for drug discovery" along with a lead clinical asset for alopecia areata.Over the past five years, the company has leveraged its proprietary platform as a source for external partnerships and has had four validating partnership deals, the analyst continued. The most recent partnership related to the acquisition of CTP-656 which is under FTC review before the final close date in October.While there is "little clarity" into the review process of CTP-656, investors should believe in the "fundamental value of a deuterated potentiator to the many players still eager to assemble the best-in-class triple combo for cystic fibrosis," Fein stated.CTP-543The recent clinical hold lift of Concert's CTP-543, a deuterated ruxolitinib (a JAK1/2 inhibitor), for the treatment of adults with moderate-to-severe AA, should be viewed as the removal of an overhang and clears a path for a phase 2a readout in the bottom half of 2018, Fein also noted."We suspect that this clinical hold may [have] less to do with endogenous factors (e.g., the compound or trial itself), and more to do with exogenous factors (e.g., the evolving sphere of research around AA field and JAK inhibitor research broadly)," he wrote. "As such, we applaud management's attitude in starting an open and conciliatory dialogue with the agency early on to prevent any possible negative downstream scenarios and allow the data to speak for itself." (7/24/2017)

Who are some of Concert Pharmaceuticals' key competitors?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:

  • Richard H. Aldrich, Chairman of the Board, Co-Founder (Age 62)
  • Roger D. Tung Ph.D., President, Chief Executive Officer, Co-Founder, Director (Age 57)
  • Ryan Lynch, Principal Financial Officer, Principal Accounting Officer
  • Nancy Stuart, Chief Operating Officer (Age 55)
  • Robert Silverman Ph.D. J.D., Senior Vice President and General Counsel (Age 62)
  • James Cassella, , Senior Vice President, chief development officer
  • Christine Boisclair, Vice President - Regulatory Affairs
  • Scott Weintraub, Vice President - Commercial and Product Strategy
  • Thomas G. Auchincloss Jr., Director (Age 52)
  • Ronald W. Barrett Ph.D., Director (Age 60)

Who owns Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (5.33%), Lyon Street Capital LLC (2.03%), Alyeska Investment Group L.P. (1.62%), Senvest Management LLC (1.38%), Dimensional Fund Advisors LP (1.18%) and Citadel Advisors LLC (0.55%). Company insiders that own Concert Pharmaceuticals stock include Pauline Mcgowan, Roger D Tung, Ryan Lynch, Thomas G Auchincloss, Value Fund L P Biotechnology and Wilfred E Jaeger. View Institutional Ownership Trends for Concert Pharmaceuticals.

Who sold Concert Pharmaceuticals stock? Who is selling Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Prudential Financial Inc., Dimensional Fund Advisors LP and California State Teachers Retirement System. View Insider Buying and Selling for Concert Pharmaceuticals.

Who bought Concert Pharmaceuticals stock? Who is buying Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Senvest Management LLC, Ingalls & Snyder LLC, First Manhattan Co., Point72 Asset Management L.P., Lyon Street Capital LLC, Princeton Capital Management Inc., SG Americas Securities LLC and Alyeska Investment Group L.P.. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Roger D Tung, Thomas G Auchincloss and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy Concert Pharmaceuticals stock?

Shares of Concert Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of Concert Pharmaceuticals stock can currently be purchased for approximately $22.22.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $504.64 million and generates $170,000.00 in revenue each year. The biotechnology company earns $-50,720,000.00 in net income (profit) each year or $3.72 on an earnings per share basis. Concert Pharmaceuticals employs 69 workers across the globe.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 99 HAYDEN AVENUE SUITE 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]


MarketBeat Community Rating for Concert Pharmaceuticals (CNCE)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Concert Pharmaceuticals (NASDAQ:CNCE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.75 (11.39% upside)

Consensus Price Target History for Concert Pharmaceuticals (NASDAQ:CNCE)

Price Target History for Concert Pharmaceuticals (NASDAQ:CNCE)

Analysts' Ratings History for Concert Pharmaceuticals (NASDAQ:CNCE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017HC WainwrightReiterated RatingBuy$21.00N/AView Rating Details
10/26/2017MizuhoInitiated CoverageBuy$23.00N/AView Rating Details
10/22/2017Stifel NicolausReiterated RatingBuy$30.00N/AView Rating Details
6/12/2017AegisReiterated RatingBuy$25.00LowView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$32.00N/AView Rating Details
9/7/2016Brean CapitalReiterated RatingBuy$25.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Concert Pharmaceuticals (NASDAQ:CNCE)

Earnings by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Earnings History by Quarter for Concert Pharmaceuticals (NASDAQ CNCE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.62)($0.58)$0.20 million$0.02 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.54)($0.60)$0.02 millionViewListenView Earnings Details
3/6/2017Q4 2016($0.66)($0.54)$0.02 millionViewListenView Earnings Details
11/8/2016Q316($0.63)($0.51)$0.06 million$0.03 millionViewListenView Earnings Details
8/9/2016Q2($0.63)($0.60)$0.06 million$0.07 millionViewN/AView Earnings Details
5/5/2016Q116($0.45)($0.63)$1.66 million$0.06 millionViewN/AView Earnings Details
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details
8/5/2015Q215($0.46)($0.40)$1.66 million$3.25 millionViewListenView Earnings Details
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details
2/27/2015Q414($0.60)($0.48)$1.77 million$1.31 millionViewN/AView Earnings Details
11/12/2014Q314($0.45)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.40)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Concert Pharmaceuticals (NASDAQ:CNCE)
Current Year EPS Consensus Estimate: $4.1 EPS
Next Year EPS Consensus Estimate: $-2.35 EPS

Dividends

Dividend History for Concert Pharmaceuticals (NASDAQ:CNCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Concert Pharmaceuticals (NASDAQ CNCE)

Insider Ownership Percentage: 10.10%
Institutional Ownership Percentage: 60.97%
Insider Trades by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Insider Trades by Quarter for Concert Pharmaceuticals (NASDAQ CNCE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/19/2017Value Fund L P BiotechnologyInsiderBuy331,916$15.84$5,257,549.44View SEC Filing  
9/14/2017Ryan LynchInsiderSell3,500$14.51$50,785.00View SEC Filing  
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.00View SEC Filing  
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50View SEC Filing  
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.64View SEC Filing  
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.00View SEC Filing  
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Concert Pharmaceuticals (NASDAQ CNCE)

Source:
DateHeadline
Concert Pharmaceuticals, Inc. (CNCE) Receives Consensus Rating of "Hold" from AnalystsConcert Pharmaceuticals, Inc. (CNCE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 20 at 5:44 PM
Concert Pharma (CNCE) Presents At Jefferies 2017 London Healthcare Conference - SlideshowConcert Pharma (CNCE) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 9:35 PM
Concert Pharmaceuticals Sees Unusually High Options Volume (CNCE)Concert Pharmaceuticals Sees Unusually High Options Volume (CNCE)
www.americanbankingnews.com - November 17 at 1:26 AM
Concert Pharmaceuticals, Inc. (CNCE) Stock Rating Upgraded by Zacks Investment ResearchConcert Pharmaceuticals, Inc. (CNCE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 15 at 9:00 PM
 Analysts Expect Concert Pharmaceuticals, Inc. (CNCE) Will Announce Earnings of $2.63 Per Share Analysts Expect Concert Pharmaceuticals, Inc. (CNCE) Will Announce Earnings of $2.63 Per Share
www.americanbankingnews.com - November 12 at 8:38 AM
Concert Pharmaceuticals, Inc. (CNCE) Rating Reiterated by HC WainwrightConcert Pharmaceuticals, Inc. (CNCE) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - November 12 at 12:58 AM
Concert Pharmaceuticals (CNCE) CEO Roger Tung on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaConcert Pharmaceuticals' (CNCE) CEO Roger Tung on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 10 at 5:22 AM
Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company UpdateConcert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - November 10 at 5:22 AM
Concert Pharmaceuticals, Inc. to Host Earnings CallConcert Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 10 at 5:22 AM
Edited Transcript of CNCE earnings conference call or presentation 9-Nov-17 1:30pm GMTEdited Transcript of CNCE earnings conference call or presentation 9-Nov-17 1:30pm GMT
finance.yahoo.com - November 10 at 5:22 AM
Concert posts 3Q profitConcert posts 3Q profit
finance.yahoo.com - November 10 at 5:22 AM
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial - Business Wire (press release)Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial - Business Wire (press release)
www.businesswire.com - November 6 at 11:36 PM
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a TrialConcert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial
finance.yahoo.com - November 6 at 6:35 PM
Is It The Right Time To Buy Concert Pharmaceuticals Inc (CNCE)?Is It The Right Time To Buy Concert Pharmaceuticals Inc (CNCE)?
finance.yahoo.com - November 6 at 6:35 PM
Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at ... - Business Wire (press release)Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at ... - Business Wire (press release)
www.businesswire.com - November 2 at 6:16 PM
Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor ConferencesConcert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences
finance.yahoo.com - November 2 at 6:16 PM
Concert Pharmaceuticals, Inc. (CNCE) Scheduled to Post Earnings on MondayConcert Pharmaceuticals, Inc. (CNCE) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 9:14 AM
$20,000.00 in Sales Expected for Concert Pharmaceuticals, Inc. (CNCE) This Quarter$20,000.00 in Sales Expected for Concert Pharmaceuticals, Inc. (CNCE) This Quarter
www.americanbankingnews.com - October 25 at 9:54 PM
ATOS Catches Eyes, PTIE Gains, CNCE Hits Right Notes, SMMT Keeps SlidingATOS Catches Eyes, PTIE Gains, CNCE Hits Right Notes, SMMT Keeps Sliding
www.nasdaq.com - October 25 at 12:43 AM
Concert Pharmaceuticals, Inc. (CNCE) Lowered to "Sell" at Zacks Investment ResearchConcert Pharmaceuticals, Inc. (CNCE) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - October 24 at 5:28 PM
Value Fund L. P. Biotechnology Buys 331,916 Shares of Concert Pharmaceuticals, Inc. (CNCE) StockValue Fund L. P. Biotechnology Buys 331,916 Shares of Concert Pharmaceuticals, Inc. (CNCE) Stock
www.americanbankingnews.com - October 23 at 7:26 PM
-$0.54 Earnings Per Share Expected for Concert Pharmaceuticals, Inc. (CNCE) This Quarter-$0.54 Earnings Per Share Expected for Concert Pharmaceuticals, Inc. (CNCE) This Quarter
www.americanbankingnews.com - October 23 at 8:30 AM
Concert Pharmaceuticals, Inc. (CNCE) Given Buy Rating at Stifel NicolausConcert Pharmaceuticals, Inc. (CNCE) Given Buy Rating at Stifel Nicolaus
www.americanbankingnews.com - October 22 at 8:22 AM
Concert Pharmaceuticals, Inc. (CNCE) Given Buy Rating at HC WainwrightConcert Pharmaceuticals, Inc. (CNCE) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - October 20 at 7:04 PM
Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 PatentConcert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent
finance.yahoo.com - October 19 at 5:50 PM
Why General Electric, Concert Pharmaceuticals, and NVR Jumped TodayWhy General Electric, Concert Pharmaceuticals, and NVR Jumped Today
finance.yahoo.com - October 19 at 5:50 PM
Concert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : October 17, 2017Concert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : October 17, 2017
finance.yahoo.com - October 17 at 6:05 PM
Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : October 16, 2017Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : October 16, 2017
finance.yahoo.com - October 16 at 6:08 PM
Concert Pharmaceuticals (CNCE) vs. Its Rivals Financial ComparisonConcert Pharmaceuticals (CNCE) vs. Its Rivals Financial Comparison
www.americanbankingnews.com - October 12 at 4:32 AM
Concert Pharmaceuticals, Inc. (CNCE) Downgraded by Zacks Investment Research to "Hold"Concert Pharmaceuticals, Inc. (CNCE) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - October 10 at 6:28 PM
Concert Pharmaceuticals, Inc. (CNCE) Expected to Announce Earnings of -$0.54 Per ShareConcert Pharmaceuticals, Inc. (CNCE) Expected to Announce Earnings of -$0.54 Per Share
www.americanbankingnews.com - October 4 at 12:26 PM
Concert Pharmaceuticals Inc (CNCE) Receives Average Rating of "Buy" from AnalystsConcert Pharmaceuticals Inc (CNCE) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 1 at 4:52 PM
Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : September 21, 2017Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : September 21, 2017
finance.yahoo.com - September 21 at 5:15 PM
Concert Pharmaceuticals (CNCE) Buy Rating Reaffirmed at HC WainwrightConcert Pharmaceuticals' (CNCE) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - September 18 at 10:16 PM
Concert Pharmaceuticals, Inc. (CNCE) Insider Sells $50,785.00 in StockConcert Pharmaceuticals, Inc. (CNCE) Insider Sells $50,785.00 in Stock
www.americanbankingnews.com - September 18 at 8:08 PM
Concert Pharmaceuticals (CNCE) & Its Competitors Financial AnalysisConcert Pharmaceuticals (CNCE) & Its Competitors Financial Analysis
www.americanbankingnews.com - September 14 at 6:06 AM
Concert Pharmaceuticals, Inc. (CNCE) Receives Consensus Rating of "Buy" from BrokeragesConcert Pharmaceuticals, Inc. (CNCE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 6 at 6:46 PM
Concert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare ConferenceConcert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference
finance.yahoo.com - August 31 at 5:15 PM
 Brokerages Expect Concert Pharmaceuticals, Inc. (CNCE) Will Announce Quarterly Sales of $20,000.00 Brokerages Expect Concert Pharmaceuticals, Inc. (CNCE) Will Announce Quarterly Sales of $20,000.00
www.americanbankingnews.com - August 30 at 11:28 AM
 Analysts Anticipate Concert Pharmaceuticals, Inc. (CNCE) Will Post Earnings of -$0.54 Per Share Analysts Anticipate Concert Pharmaceuticals, Inc. (CNCE) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - August 28 at 9:54 AM
Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 22, 2017Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 22, 2017
finance.yahoo.com - August 24 at 5:29 PM
Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:29 PM
Concert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : August 23, 2017Concert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : August 23, 2017
finance.yahoo.com - August 23 at 5:55 PM
Edited Transcript of CNCE earnings conference call or presentation 8-Aug-17 12:30pm GMTEdited Transcript of CNCE earnings conference call or presentation 8-Aug-17 12:30pm GMT
finance.yahoo.com - August 13 at 9:58 PM
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Receives Consensus Recommendation of "Buy" from AnalystsConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 12 at 6:56 PM
Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 11, 2017Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 11, 2017
finance.yahoo.com - August 11 at 5:44 PM
Concert Pharmaceuticals, Inc. (CNCE) Posts  Earnings Results, Beats Estimates By $0.04 EPSConcert Pharmaceuticals, Inc. (CNCE) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - August 9 at 5:54 PM
Concert Pharma Q2 Net Loss Slightly NarrowsConcert Pharma Q2 Net Loss Slightly Narrows
www.rttnews.com - August 8 at 5:02 PM
Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company UpdateConcert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - August 8 at 5:02 PM
Concert reports 2Q lossConcert reports 2Q loss
finance.yahoo.com - August 8 at 5:02 PM

Social Media

Financials

Chart

Concert Pharmaceuticals (NASDAQ CNCE) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.